Cargando…
Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
BACKGROUND: Mirabegron is a human β(3)-adrenoceptor agonist for the treatment of overactive bladder. The pharmacokinetic profile of mirabegron has been extensively characterized in healthy Caucasian subjects. OBJECTIVE: The objective of this study was to evaluate the pharmacokinetics, dose-proportio...
Autores principales: | Iitsuka, Hiromi, Tokuno, Tomoaki, Amada, Yoko, Matsushima, Hiroshi, Katashima, Masataka, Sawamoto, Taiji, Takusagawa, Shin, van Gelderen, Marcel, Tanaka, Takanori, Miyahara, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880470/ https://www.ncbi.nlm.nih.gov/pubmed/24178236 http://dx.doi.org/10.1007/s40261-013-0146-1 |
Ejemplares similares
-
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014) -
Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012) -
Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022) -
Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder
por: Igawa, Yasuhiko, et al.
Publicado: (2010) -
The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)